Abstract
Objective: This study was undertaken to determine plasma and pelvic tissue concentrations of piperacillin/tazobactam following a single intravenous administration.
Methods: Plasma and tissue samples were obtained following administration of 3 g of piperacillin and 0.375 g of tazobactam. Concentrations of these agents were determined by chromatography.
Results: Plasma concentrations (mean ±SD) for piperacillin/tazobactam were 208 ± 87/27 ± 8 and 95 ± 53/14 ± 2, respectively, at 30 and 60 min after the start of the infusion. The 8:1 ratio between piperacillin and tazobactam in plasma remained constant for up to 96 min. Tissue concentrations yielded a broader range, but each agent achieved significant penetration in each of the tissues studied.
Conclusions: Piperacillin/tazobactam demonstrates favorable penetration in female genital tract tissues and Should be considered a potentially effective agent for female pelvic infections.
Full Text
The Full Text of this article is available as a PDF (369.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Eklund A. E., Nord C. E. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. J Antimicrob Chemother. 1993 Jan;31 (Suppl A):79–85. doi: 10.1093/jac/31.suppl_a.79. [DOI] [PubMed] [Google Scholar]
- Gatermann S., Marre R. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases. Infection. 1991 Mar-Apr;19(2):106–109. doi: 10.1007/BF01645578. [DOI] [PubMed] [Google Scholar]
- Martens M. G., Faro S., Maccato M., Riddle G., Hammill H. A. Susceptibility of female pelvic pathogens to oral antibiotic agents in patients who develop postpartum endometritis. Am J Obstet Gynecol. 1991 May;164(5 Pt 2):1383–1386. doi: 10.1016/0002-9378(91)91477-e. [DOI] [PubMed] [Google Scholar]
- Marunaka T., Maniwa M., Matsushima E., Minami Y. High-performance liquid chromatographic determination of a new beta-lactamase inhibitor and its metabolite in combination therapy with piperacillin in biological materials. J Chromatogr. 1988 Sep 23;431(1):87–101. doi: 10.1016/s0378-4347(00)83072-8. [DOI] [PubMed] [Google Scholar]
- Ocampo A. P., Hoyt K. D., Wadgaonkar N., Carver A. H., Puglisi C. V. Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography. J Chromatogr. 1989 Nov 10;496(1):167–179. doi: 10.1016/s0378-4347(00)82563-3. [DOI] [PubMed] [Google Scholar]
- Peterson H. B., Walker C. K., Kahn J. G., Washington A. E., Eschenbach D. A., Faro S. Pelvic inflammatory disease. Key treatment issues and options. JAMA. 1991 Nov 13;266(18):2605–2611. doi: 10.1001/jama.266.18.2605. [DOI] [PubMed] [Google Scholar]
- Stein G. E. Patient costs for prophylaxis and treatment of obstetric and gynecologic surgical infections. Am J Obstet Gynecol. 1991 May;164(5 Pt 2):1377–1380. doi: 10.1016/0002-9378(91)91475-c. [DOI] [PubMed] [Google Scholar]
- Wise R., Logan M., Cooper M., Andrews J. M. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother. 1991 Jun;35(6):1081–1084. doi: 10.1128/aac.35.6.1081. [DOI] [PMC free article] [PubMed] [Google Scholar]